Sierra Research’s team has developed the algorithms that lead to the data of the following article: https://pubs.acs.org/doi/abs/10.1021/acssensors.0c00567
Plasmonic nanoparticles conjugated with anti-CA125 antibody were used to quantify MUC16 binding on leukocytes of ovarian cancer patients. Results show an elevated presence of MUC16 on ovarian cnacer patients with respect to healthy controls. Further, the assay was used for patient follow-up, showing an elevation in MUC16 binding months earlier than the elevation on serum CA125.
